Skip to main content
padlock icon - secure page this page is secure

Open Access Establishment of a secure differentiation and de-differentiation-inducing method by protein transduction system LENA

Download Article:
 Download
(PDF 276.9 kb)
 
The LENA method for gene therapy promises to be a safer technique for gene editing and cell fate redirection than current methods which can have unwanted effects, including insertional carcinogenesis and carcinogenic overexpression of the delivered gene. Gene therapy is a broad term for a range of methods which modify the genetic code of a host cell with the aim of fighting or preventing disease. Researchers are working on gene therapies to fight many different conditions including immune-deficiencies, Parkinson's Disease and haemophilia. The underlying premise is that a mutated or deficient gene in the patient's cells can be replaced with a properly functioning DNA segment, edited to function normally, or be deleted to prevent it causing future disease. However, gene therapy currently remains a highly promising technique that is still mostly practised in vitro or in animal models, as researchers strive to perfect reliable and consistent methods of delivery without serious side-effects.

For the last three years, Dr Jun Komano, Head of the Clinical Laboratory at Nagoya Medical Centre in Japan, has been working to perfect a method of changing cell DNA, which he hopes will avoid some of the downsides associated with other methods of gene editing. The LENA project achieves protein transduction using a pseudo-typed lentivirus nano-particle, which promises to be a safer method for cell fate redirection and gene-editing. He points out: 'a technology to deliver gene editing in a highly regulated manner, without damaging the host cell genome and predisposing cells to becoming malignant, is necessary for gene therapy to become a practical and effective means of treating disease in the clinic.'
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: CARCINOGENIC OVEREXPRESSION; CELL FATE REDIRECTION; GENE EDITING; GENE THERAPY; IMMUNE-DEFICIENCIES; INSERTIONAL CARCINOGENESIS; LENA METHOD; NANO-PARTICLE; PROTEIN TRANSDUCTION

Document Type: Research Article

Publication date: March 1, 2018

More about this publication?
  • Impact is a series of high-quality, open access and free to access science reports designed to enable the dissemination of research impact to key stakeholders. Communicating the impact and relevance of research projects across a large number of subjects in a content format that is easily accessible by an academic and stakeholder audience. The publication features content from the world's leading research councils, policy groups, universities and research projects. Impact is published under a CC-BY Creative Commons licence.

  • Subscribe to this Title
  • Terms & Conditions
  • Disseminating research in Impact
  • Information about Impact
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more